Li-Fen Lee, based in Singapore, is currently a Chief Executive Officer at Apeximmune Therapeutics, bringing experience from previous roles at Pharmacyclics, NGM Biopharmaceuticals, Pfizer and Stanford University School of Medicine. Li-Fen Lee holds a Ming University. With a robust skill set that includes Immunology, Target Discovery and Validation, In Vivo and in Vitro Immunoassay, Cancer Immunotherapy, Autoimmune Disease Models and more, Li-Fen Lee contributes valuable insights to the industry. Li-Fen Lee has 2 emails on RocketReach.